Christie R Eheman1, Mary Elizabeth O'Neil1, Timothy S Styles1, Trevor D Thompson1, Cyllene R Morris2, Frances A Babcock1, Vivien W Chen3. 1. Cancer Surveillance Branch, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. California Cancer Reporting and Epidemiologic Surveillance (CalCARES) Program, IPHI, UC Davis Health System, Sacramento, California. 3. Louisiana Tumor Registry and Epidemiology Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana.
Abstract
Background: Some guidelines advise adjuvant chemotherapy be considered after surgical resection for high-risk stage II colon cancer patients; however, high-risk criteria are poorly defined and the long-term benefits are still debated. This study documents patterns of care by selected patient and tumor characteristics using a US population-based cohort of stage II colon cancer patients diagnosed in 2011. Methods: Data were collected from 10 specialized cancer registries participating in the Centers for Disease Control and Prevention's National Program of Cancer Registries' Enhancing Cancer Registry Data for Comparative Effectiveness Research project. The data were used to describe characteristics of stage II colon cancer patients treated by surgery to evaluate factors associated with receiving adjuvant chemotherapy. Results: Of the 3,891 stage II colon cancer patients, 14.3% were treated with surgery and adjuvant chemotherapy compared to 82.9% by surgery alone. The patients treated with adjuvant chemotherapy were predominately non-Hispanic white (66.1%), of younger age, and had private insurance (39.9%). Compared to surgery alone, the 5 characteristics associated with adjuvant therapy were younger age (adjusted odds ratio [AOR] for 5-year decrease below 75 years, 1.25; P < .001); more advanced stage (IIB/IIC vs IIA) (AOR, 4.79; P < .001); lymphovascular invasion (AOR, 1.76, P < .001); higher grade (III/IV vs I/II) (AOR, 1.84; P < .001); and registry area. Conclusions: In this population-based cohort, younger patients with more advanced stage II colon tumors, with lymphovascular invasion, and poor differentiation were more likely to receive adjuvant chemotherapy in addition to surgery. These characteristics align with high-risk profiles defined in guidelines. Ongoing data collection on outcomes, including recurrence and survival, will help clarify the benefits of adjuvant treatments for stage II colon patients.
Background: Some guidelines advise adjuvant chemotherapy be considered after surgical resection for high-risk stage II colon cancerpatients; however, high-risk criteria are poorly defined and the long-term benefits are still debated. This study documents patterns of care by selected patient and tumor characteristics using a US population-based cohort of stage II colon cancerpatients diagnosed in 2011. Methods: Data were collected from 10 specialized cancer registries participating in the Centers for Disease Control and Prevention's National Program of Cancer Registries' Enhancing Cancer Registry Data for Comparative Effectiveness Research project. The data were used to describe characteristics of stage II colon cancerpatients treated by surgery to evaluate factors associated with receiving adjuvant chemotherapy. Results: Of the 3,891 stage II colon cancerpatients, 14.3% were treated with surgery and adjuvant chemotherapy compared to 82.9% by surgery alone. The patients treated with adjuvant chemotherapy were predominately non-Hispanic white (66.1%), of younger age, and had private insurance (39.9%). Compared to surgery alone, the 5 characteristics associated with adjuvant therapy were younger age (adjusted odds ratio [AOR] for 5-year decrease below 75 years, 1.25; P < .001); more advanced stage (IIB/IIC vs IIA) (AOR, 4.79; P < .001); lymphovascular invasion (AOR, 1.76, P < .001); higher grade (III/IV vs I/II) (AOR, 1.84; P < .001); and registry area. Conclusions: In this population-based cohort, younger patients with more advanced stage II colon tumors, with lymphovascular invasion, and poor differentiation were more likely to receive adjuvant chemotherapy in addition to surgery. These characteristics align with high-risk profiles defined in guidelines. Ongoing data collection on outcomes, including recurrence and survival, will help clarify the benefits of adjuvant treatments for stage II colonpatients.
Entities:
Keywords:
National Program of Cancer Registries; adjuvant; cancer registries; chemotherapy; colonic neoplasms; stage II
Authors: Vivien W Chen; Christie R Eheman; Christopher J Johnson; Monique N Hernandez; David Rousseau; Timothy S Styles; Dee W West; Meichin Hsieh; Anne M Hakenewerth; Maria O Celaya; Randi K Rycroft; Jennifer M Wike; Melissa Pearson; Judy Brockhouse; Linda G Mulvihill; Kevin B Zhang Journal: J Registry Manag Date: 2014
Authors: David K Espey; Charles L Wiggins; Melissa A Jim; Barry A Miller; Christopher J Johnson; Tom M Becker Journal: Cancer Date: 2008-09-01 Impact factor: 6.860
Authors: Diana Sarfati; Sarah Hill; Tony Blakely; Bridget Robson; Gordon Purdie; Elizabeth Dennett; Donna Cormack; Kevin Dew Journal: BMC Cancer Date: 2009-04-20 Impact factor: 4.430
Authors: W Schippinger; H Samonigg; R Schaberl-Moser; R Greil; R Thödtmann; J Tschmelitsch; M Jagoditsch; G G Steger; R Jakesz; F Herbst; F Hofbauer; H Rabl; P Wohlmuth; M Gnant; J Thaler Journal: Br J Cancer Date: 2007-09-25 Impact factor: 7.640